Cabaletta Bio Inc (CABA)

$2.91 +0.02 (0.69%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	489.99M
Revenue (ttm)	0.00
Net Income (ttm)	-167.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	6,979,900
Avg Vol	4,736,754
Day's Range	N/A - N/A
Shares Out	169.55M
Stochastic %K	76%
Beta	3.30
Analysts	Strong Sell
Price Target	$13.25

Company Profile

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythe...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 759 3100

Website: www.cabalettabio.com

Address:

2929 Arch Street, Suite 600, Philadelphia, United States